Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Taysha Gene Therapies (TSHA) Free Cash Flow (2022 - 2025)

Taysha Gene Therapies (TSHA) has disclosed Free Cash Flow for 4 consecutive years, with -$27.0 million as the latest value for Q4 2025.

  • Quarterly Free Cash Flow fell 47.34% to -$27.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$93.8 million through Dec 2025, down 14.99% year-over-year, with the annual reading at -$93.8 million for FY2025, 14.99% down from the prior year.
  • Free Cash Flow hit -$27.0 million in Q4 2025 for Taysha Gene Therapies, down from -$24.3 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of $12.4 million in Q4 2022 to a low of -$47.0 million in Q3 2022.
  • Historically, Free Cash Flow has averaged -$22.3 million across 4 years, with a median of -$21.7 million in 2024.
  • Biggest YoY gain for Free Cash Flow was 69.11% in 2023; the steepest drop was 226.68% in 2023.
  • Year by year, Free Cash Flow stood at $12.4 million in 2022, then tumbled by 226.68% to -$15.7 million in 2023, then fell by 16.51% to -$18.3 million in 2024, then plummeted by 47.34% to -$27.0 million in 2025.
  • Business Quant data shows Free Cash Flow for TSHA at -$27.0 million in Q4 2025, -$24.3 million in Q3 2025, and -$20.5 million in Q2 2025.